Lantern Pharma Inc. Foreign Currency Transaction Gain (Loss), before Tax
Lantern Pharma Inc. (LTRN) reported Foreign Currency Transaction Gain (Loss), before Tax of $80.84 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-14
- Lantern Pharma Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $3.55K, a 96.84% decline year-over-year.
- Lantern Pharma Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was $77.29K, a 347.31% increase year-over-year.
- Lantern Pharma Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $19.49K.
- Lantern Pharma Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $8.91K, a 88.65% decline year-over-year.
- Lantern Pharma Inc. foreign currency transaction gain (loss), before tax for fiscal 2025 was $157.97K.
- Lantern Pharma Inc. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$219.73K.
- Lantern Pharma Inc. foreign currency transaction gain (loss), before tax for fiscal 2023 was -$11.50K.
- Lantern Pharma Inc. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$58.60K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $80.84K 10-Q · filed 2026-08-14 | $100.32K derived: sum of 3 quarters · filed 2026-08-14 | $109.24K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $77.29K 10-Q · filed 2026-05-15 | $96.77K derived: sum of 2 quarters · filed 2026-05-15 | $105.69K derived: sum of 3 quarters · filed 2026-05-15 | $217.97K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $19.49K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $28.40K derived: sum of 2 quarters · filed 2026-03-30 | $140.69K derived: sum of 3 quarters · filed 2026-08-14 | $157.97K 10-K · filed 2026-03-30 |
| 2025-09-30 | $8.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $121.20K derived: sum of 2 quarters · filed 2026-08-14 | $138.48K 10-Q · filed 2025-11-12 | -$109.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $112.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $129.56K 10-Q · filed 2026-08-14 | -$117.91K derived: sum of 3 quarters · filed 2026-08-14 | -$39.39K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $17.28K 10-Q · filed 2026-05-15 | -$230.20K derived: sum of 2 quarters · filed 2026-05-15 | -$151.67K derived: sum of 3 quarters · filed 2026-05-15 | -$103.11K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$247.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$168.95K derived: sum of 2 quarters · filed 2026-03-30 | -$120.39K derived: sum of 3 quarters · filed 2026-03-30 | -$219.73K 10-K · filed 2026-03-30 |
| 2024-09-30 | $78.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $127.08K derived: sum of 2 quarters · filed 2025-11-12 | $27.75K 10-Q · filed 2025-11-12 | $145.93K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $48.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$50.78K 10-Q · filed 2025-08-13 | $67.41K derived: sum of 3 quarters · filed 2025-08-13 | -$11.64K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$99.34K 10-Q · filed 2025-05-15 | $18.85K derived: sum of 2 quarters · filed 2025-05-15 | -$60.20K derived: sum of 3 quarters · filed 2025-05-15 | -$72.64K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $118.19K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $39.13K derived: sum of 2 quarters · filed 2025-03-27 | $26.69K derived: sum of 3 quarters · filed 2025-03-27 | -$11.50K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$79.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$91.49K derived: sum of 2 quarters · filed 2024-11-07 | -$129.69K 10-Q · filed 2024-11-07 | -$29.58K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$12.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$50.63K 10-Q · filed 2024-08-08 | $49.47K derived: sum of 3 quarters · filed 2024-08-08 | -$45.24K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$38.19K 10-Q · filed 2024-05-09 | $61.91K derived: sum of 2 quarters · filed 2024-05-09 | -$32.80K derived: sum of 3 quarters · filed 2024-05-09 | -$118.90K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $100.11K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $5.39K derived: sum of 2 quarters · filed 2024-03-18 | -$80.71K derived: sum of 3 quarters · filed 2024-03-18 | -$58.60K 10-K · filed 2024-03-18 |
| 2022-09-30 | -$94.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$180.81K derived: sum of 2 quarters · filed 2023-11-08 | -$158.70K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$86.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$63.99K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $22.11K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |